Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of invasive breast cancer~  * Previously untreated disease~* Candidate for breast-conserving surgery, as defined by both of the following:~  * Clinical stage cT1-3, cN0-2 disease~ * Clinical stage M0 disease (bone scan, chest X-ray, and liver ultrasound required at screening to exclude metastatic disease)~* HER2-positive primary tumor, defined as meeting either of the following criteria:~  * IHC 3+~ * IHC 2+ and FISH positive (centralized confirmation)~* No inflammatory breast cancer or bilateral breast cancer~  * Patients who have been treated for cancer of the contralateral breast can be included if there is at least a 5 year time interval from last systemic treatment for breast cancer before randomization into this study~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Menopausal status not specified~* WBC ≥ 3.5 x 10\^9/L~* ANC ≥ 1.5 x 10\^9/L~* Platelet count ≥ 100 x 10\^9/L~* Hb ≥ 10 g/dL~* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Serum transaminases activity ≤ 2.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min~* FEV \> 55% by MUGA or ECHO~* Spirometry and DLCO \> 50% of normal~* O_2 saturation \> 88% at rest on room air~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known hypersensitivity to everolimus, sirolimus, trastuzumab (Herceptin®), or lactulose~* No hypercholesterolemia/hypertriglyceridemia ≥ grade 3~  * No hypercholesterolemia/hypertriglyceridemia ≥ grade 2 with history of coronary artery disease (despite lipid-lowering treatment if given)~* No uncontrolled infection~* No other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, including any of the following:~  * Uncontrolled hypertension~ * Congestive cardiac failure~ * Ventricular arrhythmias~ * Active ischemic heart disease~ * Myocardial infarction within the past year~ * Chronic liver or renal disease~ * Active gastrointestinal tract ulceration~ * Severely impaired lung function~* No known history of HIV seropositivity~* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* Willing to participate in the biological investigations~* Not deprived of liberty or placed under guardianship~* Patients must be affiliated to a Social Security System~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 30 days (from the screening visit) since prior other investigational drugs~* More than 5 days (from randomization) since prior and no concurrent strong inhibitors or inducers of the isoenzyme CYP3A, including any of the following~  * Rifabutin~ * Rifampicin~ * Clarithromycin~ * Ketoconazole~ * Itraconazole~ * Voriconazole~ * Ritonavir~ * Telithromycin~* No other concurrent anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy, or radiotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive trastuzumab (Herceptin®) IV once weekly for 6 weeks. Patients then undergo surgery.
- Arm II (Type: EXPERIMENTAL): Patients receive trastuzumab as in arm I and oral everolimus once daily for 6 weeks. Within 24 hours after completing everolimus, patients undergo surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).